GFH-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to GlobalData, Phase I drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GFH-009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GFH-009 overview
GFH-009 is under development for the treatment of refractory and relapsed acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), ewing sarcoma, rhabdomyosarcoma, neuroendocrine prostate cancer and lymphoma, peripheral t-cell lymphomas (PTCL), extranodal marginal zone b-cell lymphoma (mucosa-associated lymphoid tissue or MALT-lymphoma), diffuse large b-cell lymphoma, hodgkin lymphoma (b-cell hodgkin lymphoma). The drug candidate is administered by intravenous route. It acts by targeting cyclin-dependent kinase 9 (CDK9).
SELLAS Life Sciences Group overview
SELLAS Life Sciences Group (SELLAS), formerly Galena Biopharma, develops novel cancer immunotherapeutics for multiple cancer treatments. Its pipeline product candidates include galinpepimut-S (GPS), a wilms tumor1 (WT1) protein-targeting synthetic heteroclitic epitope immunotherapeutic antigen used for the treatment of acute myeloid leukemia, ovarian cancer, malignant pleural mesothelioma, multiple myeloma and solid tumors; and Nelipepimut-S, a vaccine derived from the human epidermal growth factor 2 or HER2 protein for the prevention of breast cancer and gastric carcinomas. The company collaborates with Memorial Sloan Kettering Cancer Center (MSKCC), National Cancer Institute (NCI) and The University of Texas M.D. Anderson Cancer Center (MDACC) for conducting clinical trials targeting multiple cancer indications. SELLAS is headquartered in New York City, New York, the US.
For a complete picture of GFH-009’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
